The prospective study of focal high-dose rate brachytherapy for low or intermediate risk primary clinically localized prostate cancer
Phase 1
Suspended
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000044289
- Lead Sponsor
- Kawasaki Medical School Hospita, Department of Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Suspended
- Sex
- Male
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1.Prostate cancer region and size that unsuitable brachytherapy 2.multiple cancer region diagnosed by prostate biopsy 3.Medical history for radiation therapy of the pelvis 4.Unfit for regularly MRI examination for follow-up 5.Administration of glucocorticoid or 5-arufa reductase 6.Actively double cancer
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.The efficacy for the value of serum PSA and MRI 2.The efficacy for pathological evaluation of re-biopsy of focal radiation region
- Secondary Outcome Measures
Name Time Method The safety for focal high-dose rate brachytherapy using Irisium for clinically localized prostate cancer
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of focal HDR brachytherapy in treating localized prostate cancer?
How does focal HDR brachytherapy compare to standard external beam radiation for low/intermediate risk prostate cancer?
Which biomarkers are associated with favorable outcomes in focal HDR brachytherapy for prostate cancer?
What are the potential adverse events and management strategies for focal HDR brachytherapy in prostate cancer?
Are there any combination therapies or competitor approaches to focal HDR brachytherapy for localized prostate cancer?